SLC22A1 Variant (Pro341Leu) Test

If you take metformin, lamivudine, tramadol, or imatinib, your body relies on a transporter protein in your liver and kidneys to pull these drugs out of your bloodstream and into the cells that process them. This test looks at one specific spelling change in the gene that builds that transporter, called SLC22A1 (the gene that codes for organic cation transporter 1, or OCT1).

The Pro341Leu variant is a single-letter genetic difference that can change how the transporter recognizes certain drugs. Knowing whether you carry it gives you a piece of the picture for understanding why a medication might behave differently in you than it does in someone else, and whether your dose or side effects make biological sense.

What This Variant Actually Changes

OCT1 is a transmembrane protein, meaning it sits in the outer wall of liver and kidney cells and acts like a gate, letting positively charged drug molecules pass through. The Pro341Leu change swaps one amino acid (proline) for another (leucine) at position 341 of the protein. That swap appears to alter the shape of the gate, changing which drugs it recognizes and how efficiently it moves them.

In laboratory characterization, this variant changes the transporter's selectivity for lamivudine (an antiviral used in HIV and hepatitis B treatment), with a smaller effect on metformin handling. In one study of 2,217 Mexican adults with type 2 diabetes, this specific variant was not associated with poor blood sugar control on metformin, even though other variants in the same gene were. So the practical impact appears to be drug-specific rather than universal.

How It Connects to Metformin

Metformin, the most prescribed medication for type 2 diabetes, works mainly inside liver cells. To get there, it relies on OCT1 to carry it across the cell membrane. Reduced-function variants in this gene have been linked to higher metformin blood concentrations because less of the drug ends up inside the liver where it is supposed to act.

Several reduced-function SLC22A1 variants are also linked to gastrointestinal side effects from metformin, including nausea, diarrhea, and abdominal discomfort. Pro341Leu itself appears to have a modest effect on metformin selectivity, but the more dramatic clinical findings in the published literature come from other variants in the same gene (such as R61C and M420del), not from Pro341Leu specifically.

How It Connects to Other Drugs

Beyond metformin, OCT1 helps move several other commonly used medications. Loss-of-function variants in this transporter have been associated with reduced postoperative tramadol consumption and higher concentrations of an active tramadol metabolite in 205 surgical patients. Variants in the same gene have also been studied in chronic myeloid leukemia, where impaired OCT1 function may affect how well imatinib enters target cells, though the specific Pro341Leu variant has not been singled out in those analyses.

For lamivudine, the laboratory evidence on Pro341Leu is more direct: this is one of the substrates whose handling is clearly altered by the variant. Whether that translates into measurably different antiviral response in real patients has not been worked out in large outcome studies.

Why This Is an Exploratory Marker

This is a research-stage genetic variant. There are no consensus clinical guidelines that recommend testing for Pro341Leu before prescribing any specific drug, and no established cutpoint that says "if you carry this variant, do X." The functional evidence is real, but the link from variant to bedside decision is still being mapped.

What the test can tell you today is whether you carry the variant. What it cannot tell you is exactly how a given dose of metformin or lamivudine will behave in your body, because drug response depends on dozens of other genetic and lifestyle factors. Treat the result as one input into a larger conversation about your medications, not a verdict.

Reference Ranges

Because this is a genetic test, the result is reported as a genotype rather than a numerical level. Genotype frequencies vary by ancestry, so what counts as common in one population may be uncommon in another.

What this means for you: a single Pro/Leu or Leu/Leu result is not a diagnosis. It is a piece of pharmacogenetic context that becomes useful when paired with information about which medications you take and how you respond to them.

Tracking Your Result Over Time

Unlike most blood biomarkers, your genotype does not change. You inherit it once and carry it for life. So serial trending in the usual sense does not apply: one accurate test is enough.

What does change over time is the science around how this variant affects drug response. Pharmacogenetic guidelines are updated regularly, and a variant that has limited clinical implications today may have actionable recommendations in five years. Keep your result in your records, and revisit it whenever you start a new medication that involves OCT1, particularly metformin, lamivudine, tramadol, or imatinib.

What an Abnormal Result Should Make You Do

If your result shows you carry one or two copies of the Pro341Leu variant, the first step is not to change any medication on your own. The second step is to share the result with the clinician who manages your prescriptions, particularly if you are about to start or are already taking metformin or an antiviral that depends on OCT1.

If you are on metformin and experiencing significant gastrointestinal side effects, the result is one piece of evidence that supports investigating whether a lower dose, an extended-release formulation, or an alternative drug class might suit you better. If you are starting lamivudine, your prescriber may want to monitor response more closely. Other useful companion tests in a pharmacogenetic workup include APOE genotype for lipid medication response, MTHFR genotype for folate metabolism, and CYP2D6/CYP2C19 testing for drugs metabolized by those enzymes. A clinical pharmacist or a clinician with pharmacogenetic training is the right person to integrate these results into a coherent plan.

When Results Can Be Misleading

Genetic results from a high-quality lab are stable and reproducible, so the typical confounders that affect blood biomarkers (fasting, time of day, recent illness, recent meals) do not apply here. The interpretive risks are different:

• Variant of uncertain significance: the published evidence on Pro341Leu specifically is thinner than the evidence for other SLC22A1 variants like R61C or M420del. Do not assume findings about those variants apply to this one.
• Population frequency: how common this variant is differs by ancestry. A result that is unusual in one population may be more common in another, which can affect how it has been studied.
• Single-gene tunnel vision: drug response depends on many genes plus your kidney function, liver function, age, weight, and concurrent medications. A Pro341Leu result alone does not predict how a drug will act in you.
• Lab-to-lab differences: different labs may use different methods to call the genotype. Stick with one accredited lab when you can.

Reconciling the Mixed Evidence

You may notice that some studies link SLC22A1 variants to higher metformin levels and side effects, while the one study that specifically tested Pro341Leu in 2,217 adults with diabetes found no link to poor glycemic control. These findings are consistent rather than contradictory: SLC22A1 contains many variants, and they affect different drug substrates differently. Pro341Leu's clearest functional impact appears to be on lamivudine, with modest effects on metformin. The metformin findings that grab attention come mostly from other variants in the same gene. Read your result in that context.